CN104780917B - 基于巴氯芬和阿坎酸的黄斑变性病症的疗法 - Google Patents

基于巴氯芬和阿坎酸的黄斑变性病症的疗法 Download PDF

Info

Publication number
CN104780917B
CN104780917B CN201380048663.4A CN201380048663A CN104780917B CN 104780917 B CN104780917 B CN 104780917B CN 201380048663 A CN201380048663 A CN 201380048663A CN 104780917 B CN104780917 B CN 104780917B
Authority
CN
China
Prior art keywords
baclofen
acamprosate
amd
drug
macular degeneration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380048663.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN104780917A (zh
Inventor
D.科亨
I.楚马科夫
S.纳比罗赫金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharnext SA
Original Assignee
Pharnext SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext SA filed Critical Pharnext SA
Publication of CN104780917A publication Critical patent/CN104780917A/zh
Application granted granted Critical
Publication of CN104780917B publication Critical patent/CN104780917B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201380048663.4A 2012-07-18 2013-07-18 基于巴氯芬和阿坎酸的黄斑变性病症的疗法 Expired - Fee Related CN104780917B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261672893P 2012-07-18 2012-07-18
US61/672893 2012-07-18
PCT/EP2013/065209 WO2014013025A1 (en) 2012-07-18 2013-07-18 Baclofen and acamprosate based therapy of macular degeneration disorders

Publications (2)

Publication Number Publication Date
CN104780917A CN104780917A (zh) 2015-07-15
CN104780917B true CN104780917B (zh) 2017-09-08

Family

ID=48794112

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380048663.4A Expired - Fee Related CN104780917B (zh) 2012-07-18 2013-07-18 基于巴氯芬和阿坎酸的黄斑变性病症的疗法

Country Status (17)

Country Link
US (1) US9545389B2 (enExample)
EP (1) EP2874617B1 (enExample)
JP (1) JP6271539B2 (enExample)
KR (1) KR20150058159A (enExample)
CN (1) CN104780917B (enExample)
AU (1) AU2013291970B2 (enExample)
BR (1) BR112015001090A2 (enExample)
CA (1) CA2879114A1 (enExample)
EA (1) EA029157B1 (enExample)
ES (1) ES2729208T3 (enExample)
IL (1) IL236737B (enExample)
IN (1) IN2015DN00820A (enExample)
MX (1) MX364232B (enExample)
NZ (1) NZ704280A (enExample)
SG (1) SG11201500309VA (enExample)
WO (1) WO2014013025A1 (enExample)
ZA (1) ZA201500663B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2727587A1 (en) 2012-10-30 2014-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
WO2015063140A1 (en) * 2013-10-30 2015-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
US10905672B2 (en) 2014-02-11 2021-02-02 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009004082A2 (en) * 2007-07-05 2009-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticonvulsive pharmaceutical compositions
US20120027723A1 (en) * 2009-02-04 2012-02-02 Serge Picaud Taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
KR20110097942A (ko) 2003-08-20 2011-08-31 제노포트 인코포레이티드 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법
US20050112210A1 (en) * 2003-09-12 2005-05-26 Terry Grossman Eye nutritional supplement
WO2005066122A2 (en) 2003-12-30 2005-07-21 Xenoport, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
US20080206332A1 (en) 2007-01-11 2008-08-28 Kidney David J Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
US20090082464A1 (en) 2007-09-07 2009-03-26 Bernd Jandeleit Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US8168617B2 (en) 2007-09-07 2012-05-01 Xenoport, Inc. Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090099253A1 (en) 2007-10-15 2009-04-16 Xenoport, Inc. Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use
TW200936123A (en) 2007-11-06 2009-09-01 Xenoport Inc Use of prodrugs of GABAb agonists for treating neuropathic and musculoskeletal pain
US20100137442A2 (en) 2008-02-01 2010-06-03 Xenoport, Inc. Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
WO2009096985A1 (en) 2008-02-01 2009-08-06 Xenoport, Inc. Sustained release particulate oral dosage forms of (r)-baclofen prodrugs and methods of treatment
WO2010102071A1 (en) * 2009-03-03 2010-09-10 Xenoport, Inc. Sustained release oral dosage forms of an r-baclofen prodrug
WO2010120370A2 (en) 2009-04-17 2010-10-21 Xenoport, Inc. Gamma-amino-butyric acid derivatives as gabab receptor ligands
TR201809351T4 (tr) * 2011-03-01 2018-07-23 Pharnext Nörolojik bozuklukların baklofen ve akamprosat tabanlı terapisi.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009004082A2 (en) * 2007-07-05 2009-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticonvulsive pharmaceutical compositions
US20120027723A1 (en) * 2009-02-04 2012-02-02 Serge Picaud Taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
What is New in the Management of Age-Related Macular Degeneration?;Reema Bansal et al.;《Jounal International Medical Scineces Academy》;20100901;第23卷(第3期);169-175 *

Also Published As

Publication number Publication date
IL236737A0 (en) 2015-02-26
EA029157B1 (ru) 2018-02-28
KR20150058159A (ko) 2015-05-28
EA201500143A1 (ru) 2015-05-29
ZA201500663B (en) 2016-10-26
MX2015000777A (es) 2015-10-14
HK1209335A1 (en) 2016-04-01
NZ704280A (en) 2017-06-30
AU2013291970B2 (en) 2017-09-28
US9545389B2 (en) 2017-01-17
EP2874617A1 (en) 2015-05-27
EP2874617B1 (en) 2019-02-27
WO2014013025A1 (en) 2014-01-23
JP2015522601A (ja) 2015-08-06
CN104780917A (zh) 2015-07-15
IN2015DN00820A (enExample) 2015-06-12
SG11201500309VA (en) 2015-02-27
ES2729208T3 (es) 2019-10-30
BR112015001090A2 (pt) 2017-06-27
CA2879114A1 (en) 2014-01-23
US20150238452A1 (en) 2015-08-27
JP6271539B2 (ja) 2018-01-31
MX364232B (es) 2019-04-16
IL236737B (en) 2018-12-31
AU2013291970A1 (en) 2015-02-19

Similar Documents

Publication Publication Date Title
CN103596562B (zh) 基于巴氯芬和阿坎酸的神经性障碍疗法
US10434109B2 (en) Compositions for treating neurological disorders
AU2024227357A1 (en) Ganaxolone For Use In Treating Genetic Epileptic Disorders
CN104487062B (zh) 用于治疗帕金森病的治疗方法
CN107106521A (zh) 用于治疗帕金森病的新治疗方法
CN104780917B (zh) 基于巴氯芬和阿坎酸的黄斑变性病症的疗法
JP7027318B2 (ja) 神経障害の新規の併用療法
JP2019504101A5 (enExample)
HK1209335B (en) Baclofen and acamprosate based therapy of macular degeneration disorders
JP6158234B2 (ja) 筋萎縮性側索硬化症の治療のための新規組成物
CN115052595B (zh) 用于治疗神经学疾病或病症的新型治疗方法
JP7065880B2 (ja) アルツハイマー病のイダロピルジン系組合せ療法
CN108057033A (zh) 用于治疗肌萎缩性侧索硬化症的新组合物
EP3411025A1 (en) Novel combinatorial therapies of neurological disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170908

Termination date: 20200718